Formula Pharmaceuticals and Rockland Immunochemicals will team up for the preclinical development of Formula’s Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapies at Rockland’s R&D facility. Rockland will provide and manage Formula’s preclinical research team. In addition, Rockland will provide the classified research facilities for Formula’s preclinical development needs in its newly established, scalable 60,000 square foot R&D facility. ...